title: Similar bronchodilation with formoterol delivered by aerolizer or turbuhaler.
abstract: BACKGROUND
  In many countries, two dry powder formulations of inhaled formoterol are available for clinical use; one uses a single-dose device (Foradil, Aerolizer), and the other uses a multiple-dose device (Oxis, Turbuhaler).
  
  
  OBJECTIVE
  To study the bronchodilating effect of formoterol 12 mg when delivered via the Aerolizer and Turbuhaler devices over 12 h.
  
  
  METHODS
  Randomized, double-blind, placebo controlled crossover study. Forced expiratory volume in one second (FEV1) was monitored during a 12 h period.
  
  
  METHODS
  Nineteen nonsmoking asthma patients were included in the trial on the basis of reversibility of symptoms in response to inhaled salbutamol (either 200 or 400 mg given cumulatively; minimum reversibility 15%).
  
  
  RESULTS
  There were no significant differences between the two dry powder devices regarding the change from baseline of FEV1 over 12 h, the area under the curve of FEV1 over 12 h or the maximum value of FEV1. The improvement in FEV1 with formoterol 12 mg versus placebo was highly significant for both devices.
  
  
  CONCLUSIONS
  Formoterol is similarly effective when used as a dry powder when given by either Aerolizer or the Turbuhaler.
authors.affiliation: Göteborg University, Sahlgrenska University Hospital, Göteborg, Sweden. jan.lotvall@mailer.mednet.gu.se
authors.forename: J
authors.initials: J
authors.lastname: Lötvall
authors.forename: A
authors.initials: A
authors.lastname: Mellén
authors.forename: P
authors.initials: P
authors.lastname: Arvidsson
authors.forename: M
authors.initials: M
authors.lastname: Palmqvist
authors.forename: P
authors.initials: P
authors.lastname: Radielovic
authors.forename: J
authors.initials: J
authors.lastname: Kottakis
authors.forename: P
authors.initials: P
authors.lastname: Pfister
mesh_terms: D000280:Administration, Inhalation; D000336:Aerosols; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004983:Ethanolamines / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D005541:Forced Expiratory Volume; D000068759:Formoterol Fumarate; D006801:Humans; D008297:Male; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D011208:Powders
chemical_list: D000336:Aerosols; D001993:Bronchodilator Agents; D004983:Ethanolamines; D011208:Powders; D000068759:Formoterol Fumarate